Seres Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Seres Therapeutics şirketinin toplam hissedar öz sermayesi $23.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $178.7M ve $154.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$66.82m
Eşitlik	US$23.92m
Toplam yükümlülükler	US$154.82m
Toplam varlıklar	US$178.74m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 1S9 'nin kısa vadeli varlıkları ( $72.9M ) kısa vadeli yükümlülüklerini ( $64.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 1S9 'un kısa vadeli varlıkları ( $72.9M ) uzun vadeli yükümlülüklerini ( $90.0M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 1S9 borçsuzdur.

Borcun Azaltılması: 1S9 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 1S9 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 1S9 un, serbest nakit akışı her yıl % 17.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Seres Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

Recent updates

New minor risk - Market cap size

Third quarter 2024 earnings released: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

New major risk - Financial position

Seres Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024

Lucien Selce and MKT Capital Issue Open Letter to Board of Seres Therapeutics Regarding Reported Engagement with Nestlé

Seres Therapeutics, Inc. Announces Topline Clinical Data from Cohort 2 of its SER-155 Phase 1b Placebo-Controlled Study in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

First half 2024 earnings released: US$0.49 loss per share (vs US$0.20 loss in 1H 2023)

Seres Therapeutics, Inc. announced that it expects to receive $15.000001 million in funding from Société des Produits Nestlé S.A.

Seres Therapeutics, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nestle's Health Unit to Take Full Control of Microbiota-Based Therapeutic

New minor risk - Market cap size

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

Seres Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

Seres Therapeutics Receives Non-Compliance Letter from The Nasdaq Stock Market LLC Related to Nasdaq Listing Rule 5450(a)(1)

New minor risk - Market cap size

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

New minor risk - Financial position

Full year 2023 earnings released: US$0.89 loss per share (vs US$2.32 loss in FY 2022)

No longer forecast to breakeven

Seres Therapeutics Appoints Marella Thorell as Executive Vice President

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Forecast to breakeven in 2026

New major risk - Negative shareholders equity

Seres Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Second quarter 2023 earnings released: EPS: US$0.36 (vs US$0.70 loss in 2Q 2022)

Seres Therapeutics, Inc. and Nestle Health Science Present Late-Breaking Data on VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection in Adults, at ASM Microbe 2023

Seres Therapeutics, Inc. and Nestlé Health Science Announce U.S. Commercial Availability of VOWST™

Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.61 loss in 1Q 2022)

Full year 2022 earnings released: US$2.32 loss per share (vs US$0.71 loss in FY 2021)

Seres Therapeutics' Investigational Ser-109 Ecospor Iv Study Data Publishes in Jama Network Open

Seres Therapeutics, Inc. Announces Initiation of Enrollment in SER-155 Phase 1B Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Insufficient new directors

Seres Therapeutics, Inc. Announces the Appointment of Claire M. Fraser, Ph.D., to Its Board of Directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$0.74 profit in 3Q 2021)

Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review

Seres Therapeutics, Inc. Announces the Publication of Phase 3 Clinical Data in the Journal of the American Medical Association

Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection

Second quarter 2022 earnings released: US$0.70 loss per share (vs US$0.53 loss in 2Q 2021)

Seres Therapeutics, Inc. Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection

Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting

Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic Ser-109 for Recurrent C. Difficile Infection At the Digestive Disease Week (Ddw) Annual Meeting

First quarter 2022 earnings released: US$0.61 loss per share (vs US$0.39 loss in 1Q 2021)

Seres Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People Officer

Seres Therapeutics, Inc. Announces the Publication in the New England Journal of Medicine of Data from Its Phase 3 ECOSPOR III study evaluating SER-109

Seres Therapeutics, Inc. Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data Analysis

Seres Therapeutics Announces First Patient Enrolled in Phase 1B Study of SER-155

Third quarter 2021 earnings released: EPS US$0.74 (vs US$0.36 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.53 loss per share (vs US$0.28 loss in 2Q 2020)

Seres Therapeutics, Inc. Announces Topline Results from the Phase 2B ECO-RESET Study Evaluating SER-287 in Patients with Mild-To-Moderate Ulcerative Colitis

Seres Therapeutics, Inc.(NasdaqGS:MCRB) dropped from Russell 3000E Index

Seres Therapeutics Presents Research from Its Early-Stage Microbiome Therapeutic Oncology Programs At the 2021 American Society of Clinical Oncology (Asco) Annual Meeting

Seres Therapeutics Announces U.S. Food and Drug Administration Clearance of Investigational New Drug for SER-155

Seres Therapeutics, Inc. Presents Data Across Its Broad Microbiome Pipeline Including New 24-Week Data from Ser-109 Phase 3 Ecospor III Study in Recurrent C. Difficile Infection At Digestive Disease Week 2021

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.28 loss in 1Q 2020)

Seres Therapeutics, Inc. Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma

Full year 2020 earnings released: US$1.12 loss per share (vs US$1.24 loss in FY 2019)

Revenue beats expectations

Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis

New 90-day low: €17.40

New 90-day low: €18.80

Seres Therapeutics, Inc. Therapeutics to Present SER-109 Phase 3 Mechanistic Data At Keystone Symposium

Seres Therapeutics, Inc. Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology

New 90-day low: €19.00

New 90-day low: €19.40

Revenue misses expectations

Third quarter 2020 earnings released: US$0.36 loss per share

New 90-day high: €28.80

Seres Therapeutics Announces Initiation of Phase 1b Trial of SER-301 for the Treatment of Ulcerative Colitis

Seres Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020